JP7840923B2 - 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体 - Google Patents

呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体

Info

Publication number
JP7840923B2
JP7840923B2 JP2023501029A JP2023501029A JP7840923B2 JP 7840923 B2 JP7840923 B2 JP 7840923B2 JP 2023501029 A JP2023501029 A JP 2023501029A JP 2023501029 A JP2023501029 A JP 2023501029A JP 7840923 B2 JP7840923 B2 JP 7840923B2
Authority
JP
Japan
Prior art keywords
dihydro
phenyl
benzodiazepine
oxazine
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539985A5 (https=
JP2023539985A (ja
Inventor
バーレット，マシュー
コッカリル，ジョージ・スチュアート
グッド，ジェームズ
エイベリー，クレイグ・アレックス
コクラン，エドワード・ジェームズ
ジョーンズ，ステファン・ポール
オニオンズ，スチュアート・トーマス
ワーナー，アンドリュー・ジョセフ
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2023539985A publication Critical patent/JP2023539985A/ja
Publication of JP2023539985A5 publication Critical patent/JP2023539985A5/ja
Application granted granted Critical
Publication of JP7840923B2 publication Critical patent/JP7840923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023501029A 2020-07-07 2021-07-07 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体 Active JP7840923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2010409.7A GB202010409D0 (en) 2020-07-07 2020-07-07 Pharmaceutical compounds
GB2010409.7 2020-07-07
PCT/GB2021/051731 WO2022008911A1 (en) 2020-07-07 2021-07-07 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection

Publications (3)

Publication Number Publication Date
JP2023539985A JP2023539985A (ja) 2023-09-21
JP2023539985A5 JP2023539985A5 (https=) 2024-06-25
JP7840923B2 true JP7840923B2 (ja) 2026-04-06

Family

ID=72050502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501029A Active JP7840923B2 (ja) 2020-07-07 2021-07-07 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体

Country Status (10)

Country Link
US (1) US20230270751A1 (https=)
EP (1) EP4178964A1 (https=)
JP (1) JP7840923B2 (https=)
KR (1) KR20230035597A (https=)
CN (1) CN116075516B (https=)
BR (1) BR112023000142A2 (https=)
CA (1) CA3188752A1 (https=)
GB (1) GB202010409D0 (https=)
MX (1) MX2023000440A (https=)
WO (1) WO2022008911A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202102602D0 (en) 2021-02-24 2021-04-07 Reviral Ltd Pharmaceutical compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
WO2025153942A1 (en) 2024-01-16 2025-07-24 Pfizer Inc. Benzodiazepine pyrazolo carboxamides as n-protein inhibitors
CN121621343A (zh) * 2026-02-02 2026-03-10 云南大学 一种化合物在防控植物病原真菌尖孢镰刀菌上的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503054A (ja) 2002-09-20 2006-01-26 アロー セラピューティクス リミテッド ベンゾジアゼピン誘導体およびそれらを含有する医薬組成物
JP2018524386A (ja) 2015-07-22 2018-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
JP2022545249A (ja) 2019-08-20 2022-10-26 アールイーヴァイラル リミテッド 医薬化合物
JP2022553700A (ja) 2019-10-22 2022-12-26 アールイーヴァイラル リミテッド 呼吸器合胞体ウイルス（ｒｓｖ）感染症を治療するためのベンゾジアゼピン誘導体
JP2023539986A (ja) 2020-07-07 2023-09-21 ファイザー・インク 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
JP7667779B2 (ja) 2019-11-01 2025-04-23 ファイザー・インク 医薬化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5127096B2 (ja) * 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
GB0406280D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
US10398706B2 (en) * 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
KR101970214B1 (ko) * 2017-07-17 2019-08-27 이화여자대학교 산학협력단 유기금속 화합물, 이들의 자기 조립체 및 이를 포함한 종양 진단 또는 치료용 조성물
US10647711B2 (en) * 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503054A (ja) 2002-09-20 2006-01-26 アロー セラピューティクス リミテッド ベンゾジアゼピン誘導体およびそれらを含有する医薬組成物
JP2018524386A (ja) 2015-07-22 2018-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
JP2022545249A (ja) 2019-08-20 2022-10-26 アールイーヴァイラル リミテッド 医薬化合物
JP2022553700A (ja) 2019-10-22 2022-12-26 アールイーヴァイラル リミテッド 呼吸器合胞体ウイルス（ｒｓｖ）感染症を治療するためのベンゾジアゼピン誘導体
JP7667779B2 (ja) 2019-11-01 2025-04-23 ファイザー・インク 医薬化合物
JP2023539986A (ja) 2020-07-07 2023-09-21 ファイザー・インク 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kim, Junghwan et al.，Identification of two HIV inhibitors that also inhibit human RNaseH2，Molecules and Cells ，2013年，36(3)，p.212-218

Also Published As

Publication number Publication date
MX2023000440A (es) 2023-04-13
US20230270751A1 (en) 2023-08-31
CN116075516A (zh) 2023-05-05
EP4178964A1 (en) 2023-05-17
JP2023539985A (ja) 2023-09-21
BR112023000142A2 (pt) 2023-01-31
CN116075516B (zh) 2026-02-03
CA3188752A1 (en) 2022-01-13
KR20230035597A (ko) 2023-03-14
GB202010409D0 (en) 2020-08-19
WO2022008911A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP7840923B2 (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
JP7700196B2 (ja) Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
JP7721501B2 (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
CN107660205B (zh) 作为lsd1抑制剂的杂环化合物
DK3077395T3 (en) PYRROLO [2,3-D] PYRIMIDINYL, PYRROLO [2,3-B] PYRAZINYL AND PYRROLO [2,3-D] PYRIDINYL ACRYLAMIDS
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
JP6600365B2 (ja) Ｊａｋ阻害剤
US8552047B2 (en) Hepatitis C virus inhibitors
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
CN103249731A (zh) 丙型肝炎病毒抑制剂
TW201317215A (zh) 具治療作用之組成物及其使用方法
US11332459B2 (en) Benzimidazole derivatives and their uses
WO2015178955A1 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
RU2764980C2 (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
WO2017100668A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
WO2015096035A1 (en) Inhibitors of renal outer medullary potassium channel
KR20230035596A (ko) 호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체
CA3158169A1 (en) Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection
CA3231728A1 (en) Novel compounds
CN117813298A (zh) 作为jak抑制剂的咪唑吲唑化合物
JP7776616B2 (ja) Ｐｄ－ｌ１相互作用の免疫調節剤としての化合物
RU2840815C2 (ru) Фармацевтические соединения
HK40094055A (zh) 可用於治疗呼吸道合胞病毒感染的苯二氮杂䓬衍生物
WO2025076632A1 (en) Compounds and uses thereof
HK40102634A (zh) 作为pd-l1相互作用的免疫调节剂的化合物

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230614

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260325

R150 Certificate of patent or registration of utility model

Ref document number: 7840923

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150